Antibiotic resistant superbugs pose a global threat after breaking through last line of defence, doctors warn
Researchers have found a gene that makes bacteria resistant to the last line of antibacterial defence, and it is now being passed down through bacteria — potentially leading to a huge and unstoppable epidemic
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Superbugs have become resistant to our very last line of disease defence, according to scientists, and could be about to cause a global threat from a huge epidemic.
A gene that can allow bacteria to become resistant to polymyxins, which are the final antibiotic that doctors rely on if all others fail, has been found by Chinese scientists. There is “extremely worrying” evidence that the gene that can allow can be transferred to bacteria and make them super-resistant, leading to epidemics.
Scientists have found strains of E.coli and other diseases, which can together cause serious infections and even death.
An E.coli strain showing resistance to the polymyxin drug colistin was isolated from an intensively farmed pig in Shanghai during routine testing.
Scientists found the bug was able to transfer its immunity to the drug to other strains via the mobile gene mcr-1. This led to further tests of bacterial samples collected from pigs at slaughter in four Chinese provinces, and pork and chicken sold in 30 open markets and 27 supermarkets across Guangzhou province between 2011 and 2014.
Bacteria from infected patients at two hospitals in Guangdong and Zhejiang provinces were also tested.
A high prevalence of the resistance gene was found in E. coli bugs isolated from animals and raw meat samples. The gene was also identified in 16 E.coli and K. pneumoniae samples taken from 1,322 hospitalised patients.
Alarmingly, the proportion of samples testing positive for the super-resistance gene increased from year to year, said the scientists.
Lead researcher Professor Jian-Hua Liu, from the South China Agricultural University in Guangzhou, said: "These are extremely worrying results. The polymyxins (colistin and polymyxin B) were the last class of antibiotics in which resistance was incapable of spreading from cell to cell. Until now, colistin resistance resulted from chromosomal mutations, making the resistance mechanism unstable and incapable of spreading to other bacteria.
"Our results reveal the emergence of the first polymyxin resistance gene that is readily passed between common bacteria such as Escherichia coli and Klesbsiella pneumoniae, suggesting that the progression from extensive drug resistance to pan-drug resistance is inevitable."
It was likely that polymyxin resistance via mcr-1 originated in animals before spreading to humans, said the scientists writing in The Lancet Infectious Diseases journal.
Increasingly heavy use of colistin by Chinese farmers may have helped E.coli to acquire the gene, they added.
Worldwide, the demand for colistin in agriculture was expected to reach almost 12,000 tonnes per year by the end of this year, rising to 16,500 tonnes by 2021.
The scientists wrote: "The emergence of mcr-1 heralds the breach of the last group of antibiotics. Although currently confined to China, mcr-1 is likely to emulate other resistance genes... and spread worldwide. There is a critical need to re-evaluate the use of polymyxins in animals and for very close international monitoring and surveillance of mcr-1 in human and veterinary medicine."
The Chinese Ministry of Agriculture has launched an immediate risk assessment of colistin use in animal feed additives.
British experts called the discovery "disturbing" and "alarming".
Dr David Burch, veterinary surgeon and an independent member of the Ruma (Responsible Use of Medicines in Agriculture) Alliance, said: "The report of a new resistance gene (mcr-1) against polymixins (colistin) found in Escherichia coli from pigs in China, which can be potentially plasmid transferred between bacterial species and potentially to man via meat, is indeed disturbing and disappointing."
He pointed out that China's pig farming industry is the largest in the world, more than twice the size of Europe's. The use of generic antimicrobial drugs in animals is not normally under veterinary control in China.
The risk of the resistance gene spreading was heightened by increased trade and tourism bridging China and the West, said Dr Burch.
Professor Nigel Brown, president of the Microbiology Society, said: "This discovery that resistance to colistin can be transferred between bacteria is alarming.
"Although resistance to this important and widely-used polymyxin group of antibiotics has previously been shown, it was generally caused by mutation in individual organisms. Now that it has been demonstrated that resistance can be transferred between bacteria and across bacterial species, another line of defence against infection is in danger of being breached.
"We need careful surveillance to track the potential global spread of this resistance, and investment in research to discover new drugs with different modes of action."
Additional reporting by Press Association
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments